Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.

OBJECT A minority of patients with recurrent glioblastomas multiforme (GBMs) responds to systemic chemotherapy. The authors investigated the safety and efficacy of intratumoral convection-enhanced delivery (CED) of paclitaxel in patients harboring histologically confirmed recurrent GBMs and anaplastic astrocytomas. METHODS Fifteen patients received a total of 20 cycles of intratumoral CED of paclitaxel. The patients were observed daily by performing diffusion-weighted (DW) magnetic resonance (MR) imaging to assess the convective process and routine diagnostic MR imaging to identify the tumor response. Effective convection was determined by the progression of the hyperintense signal within the tumor on DW MR images, which corresponded to a subsequent lytic tumor response displayed on conventional MR images. Of the 15 patients, five complete responses and six partial responses were observed, giving a response rate of 73%. The antitumor effect was confirmed by one biopsy and three en bloc resections of tumors, which showed a complete response, and by one tumor resection, which demonstrated a partial response. Lack of convection and a poor tumor response was associated with leakage of the convected drug into the subarachnoid space, ventricles, and cavities formed by previous resections, and was seen in tumors containing widespread necrosis. Complications included transient chemical meningitis in six patients, infectious complications in three patients, and transient neurological deterioration in four patients (presumably due to increased peritumoral edema). CONCLUSIONS On the basis of our data we suggest that CED of paclitaxel in patients with recurrent malignant gliomas is associated with a high antitumor response rate, although it is associated with a significant incidence of treatment-associated complications. Diffusion-weighted MR images may be used to predict a response by demonstrating the extent of convection during treatment. Optimization of this therapeutic approach to enhance its efficacy and reduce its toxicity should be explored further.

[1]  J. Urquhart,et al.  Spatial distribution of dopamine, methotrexate and antipyrine during continuous intracerebral microperfusion , 1985, Brain Research.

[2]  W T Kyner,et al.  Bulk flow of brain interstitial fluid under normal and hyperosmolar conditions. , 1980, The American journal of physiology.

[3]  R. Harbaugh,et al.  Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study. , 1991, Neurosurgery.

[4]  R. Penn,et al.  Direct delivery of medication into a brain tumor through multiple chronically implanted catheters. , 1987, Neurosurgery.

[5]  P F Morrison,et al.  High-flow microinfusion: tissue penetration and pharmacodynamics. , 1994, The American journal of physiology.

[6]  A. Marmarou,et al.  Clearance of brain edema and macromolecules through the cortical extracellular space. , 1992, Journal of neurosurgery.

[7]  R. Penn,et al.  Intracerebral chemotherapy: chronic microinfusion of cisplatin. , 1982, Neurosurgery.

[8]  H. Reulen,et al.  Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema. , 1977, Journal of neurosurgery.

[9]  S E Maier,et al.  Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. , 2001, Cancer research.

[10]  I. Pastan,et al.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  A. Friedman,et al.  Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. , 1991, Journal of neurosurgery.

[12]  P. Burger,et al.  Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. , 1994, Cancer research.

[13]  P. Basser,et al.  MR diffusion tensor spectroscopy and imaging. , 1994, Biophysical journal.

[14]  M. Berger,et al.  Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Zucchetti,et al.  Do anticancer agents reach the tumor target in the human brain? , 2004, Cancer Chemotherapy and Pharmacology.

[16]  M. Jordan,et al.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Bjerkvig,et al.  Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. , 1997, British Journal of Cancer.

[18]  W. Debinski Local Treatment of Brain Tumors with Targeted Chimera Cytotoxic Proteins , 2002, Cancer investigation.

[19]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Piantadosi,et al.  Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P F Morrison,et al.  Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. , 1995, Journal of neurosurgery.

[22]  S. Maier,et al.  Line scan diffusion imaging , 1996, Magnetic resonance in medicine.